Takeda Ventures
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001 and based in San Diego, investing globally in therapeutic and platform opportunities across oncology, gastroenterology, neuroscience, and rare diseases.
- Company typePublic
- Founded2001
- HeadquartersSan Diego, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Takeda Ventures does
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001 and headquartered in San Diego. It invests in high-caliber therapeutic and platform-based opportunities globally, providing early-stage capital and strategic support to companies whose technologies align with Takeda's four core therapeutic areas: Oncology, Gastroenterology, Neuroscience, and Rare Diseases, with additional focus on Plasma-Derived Therapies and Vaccines. The arm is led by Michael Martin as Head of Takeda Ventures, Inc., and operates as one channel within Takeda's broader business development and R&D sourcing strategy.
The portfolio companies backed by Takeda Ventures benefit from Takeda's vertically integrated biopharmaceutical infrastructure, which spans the full plasma-derived therapy value chain through BioLife (more than 270 donation centers across the U.S. and Europe, 8 PDT manufacturing facilities), enterprise field-sales operations across approximately 80 countries/regions, and an annual revenue base exceeding $30 billion USD generated across Oncology, GI, Neuroscience, Rare Diseases, and PDT business areas. Notable venture-related activity includes the 2021 acquisition of GammaDelta Therapeutics (cell therapy, gamma-delta T cells) and the 2022 acquisition of NDI-034858 from Nimbus Therapeutics, illustrating the CVC-to-M&A pathway within Takeda's corporate development model.
Takeda Ventures sits within a parent organization undergoing significant digital transformation under the Takami program — a multi-year initiative standardizing end-to-end business processes on SAP S/4HANA and building AI-enabled operations across R&D, manufacturing, supply chain, and commercial functions. The parent employs approximately 50,000 people globally, holds dual listings on the Tokyo Stock Exchange (TSE:4502) and NYSE (TAK), and is led by Julie Kim as President and CEO following a 2025 leadership transition. Strategic partnerships with entities such as Innovent Biologics (oncology pipeline additions in 2025) further expand the deal-sourcing and value-creation channels available to Takeda Ventures.
Takeda Ventures firmographics
Firmographics- Name
- Takeda Ventures
- Legal name
- Takeda Pharmaceutical Company Limited
- Website
- https://www.takeda.com/what-we-do/research-and-development/takeda-ventures
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001 and based in San Diego, investing globally in therapeutic and platform opportunities across oncology, gastroenterology, neuroscience, and rare diseases.
- Ownership category
- akta.pro rank
Takeda Ventures industry classification
Industry- Product category
- Corporate Venture Capital
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Takeda Ventures is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
Takeda Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Others
Revenue model
- Pharmaceutical Product Sales: Takeda generates revenue primarily through the sale of prescription pharmaceutical products across its key business areas: Oncology, Gastroenterology, Neuroscience, Rare Diseases, and Plasma-Derived Therapies. The combined annual revenue exceeds $30 billion USD. Revenue comes from both proprietary in-line brands and newly launched products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Prescription pharmaceutical products - pricing determined through government and insurance negotiations |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Takeda Ventures product offering
Product offeringCore offering
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001 and headquartered in San Diego, California. The firm invests in high-caliber therapeutic and platform-based opportunities in the life sciences sector worldwide. It deploys capital from the parent company into early- and growth-stage biotech companies whose platforms or therapeutic assets align with Takeda's research and development priorities.
Product overview
Takeda is a global, values-based, R&D-driven biopharmaceutical company organized around four core therapeutic areas (Oncology, Gastroenterology, Neuroscience, and Rare Diseases) plus targeted investments in Plasma-Derived Therapies and Vaccines. The company operates an end-to-end integrated plasma value chain through BioLife plasma donation centers and eight PDT manufacturing facilities, producing over 20 differentiated PDT medicines. The marketed product portfolio includes established brands like ENTYVIO (vedolizumab), GAMMAGARD LIQUID, TAKHZYRO (lanadelumab-flyo), and QDENGA (dengue vaccine). The late-stage pipeline features three upcoming launches—Oveporexton (TAK-861) for narcolepsy Type 1, Rusfertide for polycythemia vera, and Zasocitinib (TAK-279) for psoriasis—targeted for 2026-2027, along with earlier-stage assets like TAK-788, Pevonedistat, Elitercept, and Mezagitamab. Digital transformation is driven by the Takami program (SAP S/4HANA-based) and AI capabilities including Smart Donor Care for plasma donation and generative AI tools used by 63% of employees.
Differentiator
Problem solved
Functional benefit
Brands
- Takami: Multi-year transformation program to redesign and standardize end-to-end business processes across Takeda while establishing SAP S/4HANA as the global digital core.
- BioLife
Products and services
- Venture Capital Investment Services
- GammaDelta Therapeutics (Acquired Portfolio Company)
Quantifiable outcome
- 58% reduction in Scope 1 & 2 emissions since FY2016, supporting goal to reduce by 90% by FY2030
- +4 more outcomes
Companies that use Takeda Ventures
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Takeda Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability11 records
Feature5 records
Takeda Ventures partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core, minor and major.
- Innovent BiologicscoreStrategic partnership with Innovent Biologics added two next-generation investigational oncology medicines to Takeda's late-stage pipeline. These medicines have potential to address critical treatment gaps for patients with a range of solid tumors, strengthening Takeda's oncology portfolio.
- AIT Austrian Institute of TechnologyminorMulti-year collaboration with AIT Austrian Institute of Technology to develop AHEAD (Advanced Heat Pump Demonstrator) at Takeda's Vienna PDT manufacturing site. AHEAD generates process steam without fossil fuels, enabling CO2-free steam generation for more than seven months annually.
- Nimbus TherapeuticsmajorTakeda acquired NDI-034858 from Nimbus Therapeutics through a conference call and investor event in December 2022. This represents a targeted business development investment aligned with Takeda's core therapeutic areas.
- Shire plccoreTakeda completed acquisition of Shire plc in January 2019, becoming a global biopharmaceutical leader. The acquisition expanded Takeda's geographic footprint and strengthened its position in rare diseases, with Shire's portfolio complementing Takeda's existing therapeutic areas. The combined company has annual revenue exceeding $30 billion USD.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Takeda Ventures competitors and assessment
Company assessmentDirect peers
- Roche Venture Fund: CVC arm of Roche investing in early-stage therapeutic and diagnostic companies worldwide. Closely comparable given similar focus on platform-based healthcare innovations and pharma-parent backing.
- Bayer LifeScience Ventures (Leaps by Bayer): Bayer's impact-focused venture arm investing in breakthrough biotech and platform technologies. Comparable as a major pharma CVC investing in transformative therapeutic opportunities globally.
- Johnson & Johnson Innovation (JJDC): Strategic venture arm of J&J investing in therapeutic and platform opportunities globally. Comparable in scale, therapeutic focus areas, and parent-company integration as a long-established pharma CVC.
- Novartis Venture Fund: Corporate venture capital arm of Novartis, investing globally in therapeutic-focused early-stage biotech companies. Directly comparable to Takeda Ventures as a strategic pharma CVC with healthcare-only investment thesis.
- Eli Lilly and Company - Lilly Ventures: Lilly's strategic investment arm funding therapeutic platform and early-stage biotech opportunities. Directly comparable as a major pharma CVC with global mandate and therapeutic specialization.
- Merck Global Health Innovation Fund: CVC arm of Merck investing in digital health and therapeutic platforms. Comparable in strategic parent backing and global healthcare investment focus.
- Sanofi Ventures: Corporate venture capital arm of Sanofi investing in early-stage biotech and digital health. Comparable as a global pharma CVC with similar therapeutic platform investment thesis.
- Pfizer Ventures: Corporate venture arm of Pfizer focused on therapeutic and platform investments across multiple disease areas. Comparable CVC structure, mandate, and global deployment strategy to Takeda Ventures.
- AbbVie Ventures: Strategic investment arm of AbbVie focused on therapeutic platforms across multiple disease areas. Comparable CVC structure focused on early-stage therapeutics and platform technologies.
Broad incumbents
- AstraZeneca - Alexion CVC activities: While not a standalone CVC, AstraZeneca has significant strategic investment activity focused on rare diseases and oncology, overlapping with Takeda Ventures' therapeutic focus areas post-Shire acquisition.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights5 records
Customer concentration
Takeda Ventures social profiles
Digital presenceTakeda Ventures compliance and trust
Trust signalCompliance2 records
Takeda Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Takeda Ventures leadership team
Management profileNumber of profiles
Profiles1 record
Takeda Ventures subsidiaries and ownership
Company hierarchySubsidiaries3 records
Takeda Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Takeda Ventures M&A and investment
M&A and investmentM&A1 record
Investments100 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Takeda Ventures
What does Takeda Ventures do?
Takeda Ventures is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001 and headquartered in San Diego, California. The firm invests in high-caliber therapeutic and platform-based opportunities in the life sciences sector worldwide. It deploys capital from the parent company into early- and growth-stage biotech companies whose platforms or therapeutic assets align with Takeda's research and development priorities.
Is Takeda Ventures a public or private company?
Takeda Ventures is a public company. It is classified as corporate owned and is currently operating.
When was Takeda Ventures founded?
Takeda Ventures was founded in 2001. It employs 5,001 to 10,000 people.
Where is Takeda Ventures based?
Takeda Ventures is headquartered in San Diego, United States, in the North America region.
How does Takeda Ventures make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Takeda Ventures's main competitors?
Direct peers on record are Roche Venture Fund, Bayer LifeScience Ventures (Leaps by Bayer), Johnson & Johnson Innovation (JJDC), Novartis Venture Fund, Eli Lilly and Company - Lilly Ventures, Merck Global Health Innovation Fund, Sanofi Ventures, Pfizer Ventures and AbbVie Ventures. AstraZeneca - Alexion CVC activities is listed as a broad incumbent.
Does Takeda Ventures have an API?
No public API is recorded for Takeda Ventures.
What industry is Takeda Ventures in?
Takeda Ventures's product category is Corporate Venture Capital. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support.